t’s no secret that the pandemic upended the life sciences industry. As COVID-19 began spreading across the world, pharma and biotechs big and small suddenly faced a slew of unprecedented challenges.

Not only did these organizations need to procure additional personal protective equipment (PPE) and other resources to keep mission-critical operations humming along, but they also needed to keep their own supply chains running smoothly as they worked to develop new drugs and vaccines in addition to the lifesaving drugs they were already manufacturing.

In these high-stakes scenarios, any kind of delay in payments or procurement could literally mean the difference between life and death.

Read the full article